分子护理点 (mPOC) 市场与前景：第 11 版

与现有的近距离患者快速检测相比，分子护理点 (mPOC) 诊断解决方案提高了灵敏度和特异性。 这些解决方案旨在扩展重症监护病房、医生办公室、门诊诊所和社区卫生站的诊断能力，以准确评估和住院患者。 这个概念将现场护理 (POC) 测试的易用性与分子技术的准确性结合起来。

本报告探讨了全球分子即时照护 (mPOC) 市场，提供市场发展和趋势、成长前景以及参与该市场的公司概况。

目录

第 1 章执行摘要

第二章分子即时照护市场发展与趋势

• COVID-19 和分子 POC
• CDC的初步因应、长期状况
• COVID-19 的独特挑战
• BARDA 资助 mPOC
• 监理趋势
• 联盟、资助和奖项
• 特价讯息
• 分子即时护理的优点和缺点
• 理由：敏感度/特异度讨论
• 新系统和选单扩展
• Mesa Biotech A 型链球菌已获批准
• 组合检测将改变市场：SARS-CoV-2、甲型流感、乙型流感、呼吸道合胞病毒
• 性传染感染仍然是一个不断发展的领域
• mPOC系统的交易与投资
• Roche以高达 3.5 亿美元收购 LumiraDx
• Thermo 收购 Mesa Biotech
• 欧盟研究人员因开发 POC 分子测试而获得 Euro-3M 奖
• Scope Fluidics 的 AST 系统获得投资
• 中国作为 POC 市场
• POC诊断的一般测试和分析目标
• 分子即时诊断的基本技术
• 微流控
• 定量 PCR
• 微阵列晶片
• 等温扩增
• 测试自动化
• 引子和探针
• 侦测
• 次世代定序
• 分子诊断
• 即时萤光定量 PCR (qPCR)
• 等温扩增法
• 线性探针侦测
• 次世代定序
• 分子护理点应用与潜在应用
• 分子POC诊断在主要检查的应用
• 流感
• RIDT 的重新分类
• 院内感染 (HAI)
• A型链球菌
• 呼吸道合胞病毒 (RSV)
• 新用途
• 寨卡热
• 其他呼吸道感染
• B 型链球菌
• 人类乳突病毒
• 单纯疱疹病毒
• 阴道炎
• 结核病
• 疟疾
• 其他被忽视的热带疾病
• 癌症
• 欧洲设备法规

第三章市场分析

• 分子即时护理市场分析
• 床边分子市场
• 床边市占率

第四章公司简介

• Abbott Laboratories
• Aidian Oy
• Akonni Biosystems
• binx health, inc.
• Biocartis NV
• bioMerieux SA
• Cepheid (Danaher)
• Molecular Healthcare-Acquired Infection (HAI) Testing
• Molecular Sexual Health and Women's Health Testing
• Molecular Critical Infectious Disease Testing
• Molecular Oncology/Genetics Testing
• Credo Diagnostics Biomedical Pte. Ltd.
• Cue Health
• Curetis NV (OpGen)
• DiaSorin S.p.A
• GenMark Diagnostics (Roche)
• Greiner Bio-One GmbH
• Lucira Health (Pfizer)
• Meridian Bioscience, Inc. (SD Biosensor)
• Mesa Biotech, Inc. (Thermo)
• QIAGEN NV
• QuantuMDx Group
• QuidelOrtho Corporation
• Roche
• Sekisui Diagnostics LLC
• T2 Biosystems

Molecular point-of-care (mPOC) diagnostic solutions offer enhanced sensitivity and specificity compared to existing near-patient and rapid tests. They expand diagnostic capabilities in critical care units, physician offices, outpatient clinics, and community health posts, aiming to assess conditions or admit patients accurately. The concept blends the accessibility of point-of-care (POC) testing with the precision of molecular technology. Kalorama Information has been covering mPOC on a regular basis since 2013.

Our latest report, “The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition”, is a valuable resource for understanding the size and growth potential of the molecular POC market from 2023-2028. mPOC has transitioned from a novel trend to a significant contributor to the market. Instruments from companies like Abbott, BioMérieux, Cepheid, and others play a substantial role in the IVD point-of-care market. Understanding these markets is crucial for assessing the opportunity in point-of-care testing and microbiology IVD.

“The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition” provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings.

Kalorama reports provide real-world analysis and modeling for relevant circumstances. Analysts offer insights into near-patient molecular testing using small instruments.

The data in “The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition” includes information on systems, competitor analysis, and the size and growth of the market.

• What are the mPOC market opportunities beyond COVID-19?
• What are the current systems on the market? Who's winning?
• What's the size of the Molecular Point-of-Care Market: 2023-2028
• Geographic Breakout of the Molecular Point-of-Care Market, 2023 (N. America, Europe, APAC, RoW)
• Segment Breakout of Molecular Point-of-Care Market, 2023 (Respiratory vs. Other)
• Near Patient Molecular IVD Market: 2023-2028
• Near Patient Molecular Market Share by Vendor, 2023
• Company Profiles

Competitive Analysis

Companies covered in this report, in profiles and/or product tables and market developments discussion include:

Scope

The market definition for molecular point-of-care can be challenging compared to other markets that Kalorama Information covers as there are competing ideas about point-of-care or near-patient tests. But the future promise of molecular point-of-care is in sample-to-answer workflows and short result times that would make systems useful for a physician lab office. Therefore, systems like Roche's cobas Liat, Abbott's ID NOW (formerly the Alere i), and bioMérieux's Biofire FilmArray 2.0 are the type of systems principally considered in market scope.

For the purposes of this report, systems must be capable of running CLIA-waived tests or have that capability in the near future. That being said there are a wide variety of molecular systems that could be classified as near-patient or rapid. Since sales of these systems may affect core markets, Kalorama also includes in the discussion and in some additional market considerations rapid molecular testing that may be challenging to define as point-of-care but have a point-of-care-like quality such as HAI or STI testing.

Table of Contents

Chapter 1: Executive Summary

• Figure 1-1: Molecular Point-of-Care Market (mPOC), 2023-2028 ($M)
• Figure 1-2: Near Patient Molecular Systems Market, 2023-2028 ($M)
• Where is Molecular Point-of-Care in 2024?
  • Table 1-1: Molecular Point-of-Care Market, 2023-2028 ($M)
• Molecular Point-of-Care Market Analysis
• Table 1-2: Molecular Point-of-Care Market Growth, 2023-2028 (%)
  • Figure 1-3: mPOC Market by Disease Indication, 2023 (%; Respiratory, Other)
• Market Observations
• "Near-Patient" Molecular Systems Market
  • Table 1-3: Near Patient Molecular Systems Market, 2023-2028 ($M)
  • Table 1-4: Near Patient Molecular Systems Market Growth, 2023-2028 (%)
  • Figure 1-4: mPOC and Near-Patient Market, 2023-2028 ($M)
  • Table 1-5: mPOC and Near-Patient Market, 2023-2028 ($M)
• Current Trends
• Molecular Point-of-Care Diagnostics Defined
• Usage of Molecular Point-of-Care
• Leading mPOC Platforms
  • Table 1-6: Molecular POC Diagnostic Platforms and Technologies
• Trends
• Scope and Methodology

Chapter 2: Molecular Point-of-Care Market Development and Trends

• COVID-19 and Molecular POC
  • Table 2-1: Molecular POC COVID-19 Emergency Authorizations
• CDC Initial Response, Long Term Situation
• COVID-19's Unique Challenge
• BARDA Directs Funding to mPOC
• Regulatory Developments
• Consortia, Funding, Prizes
• Deals
  • Table 2-2: Deals in Molecular Point-of-Care, April 2019-Feb 2024
• Advantages and Disadvantages of Molecular Point-of-Care
  • Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting (Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC)
• Justification: The Sensitivity/Specificity Argument
• New Systems and Menu Expansion
• Mesa Biotech Strep A Approval
• Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV
• STI Continues to Be a Growth Area
• Deals, Investment in mPOC Systems
• Roche Acquires LumiraDx for up to $350M
• Thermo Acquires Mesa Biotech
• EU Researchers Awarded Euro-3M to Develop POC Molecular Tests
• Scope Fluidics AST System Sees Investment
• China as a POC Market
• Common Tests and Analytes in POC Diagnostics
• Component Technologies of Molecular Point-of-Care Diagnostics
• Microfluidics
• qPCR
• Microarrays
• Isothermal Amplification
• Test Automation
• Primers and Probes
• Detection
• Next-Generation Sequencing
• Molecular Diagnostics
• Real-Time PCR (qPCR)
• Isothermal Amplification Methods
• Line Probe Assays
• Next-Generation Sequencing
• Applications and Potential Applications for Molecular Point-of-Care
• Major Testing Applications for Molecular POC Diagnostics
• Influenza
• Reclassification of RIDTs
• Hospital-Acquired Infections (HAIs)
• Strep A
• Respiratory Syncytial Virus (RSV)
• Emerging Applications
• Zika
• Other Respiratory Infections
• Group B Streptococcus
• Human Papillomavirus
• Herpes Simplex Virus
• Vaginitis
• Tuberculosis
• Malaria
• Other Tropical and Neglected Diseases
• Cancer
• European Device Regulations

Chapter 3: Market Analysis

• Molecular Point-of-Care Market Analysis
  • Table 3-1: Molecular Point-of-Care Market, 2023-2028 ($M, %)
  • Figure 3-1: Molecular Point-of-Care Market, 2023-2028 ($M)
  • Table 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region (North America, Europe, APAC, RoW), 2023 ($M, %)
  • Table 3-3: Segment Breakout of Molecular Point-of-Care Market, by Area (COVID-Respiratory vs. Other), 2023 ($M, %)
  • Figure 3-2: Breakout of Molecular Point-of-Care Market (Respiratory, Other), 2023 (%)
• "Near Patient Molecular" Market
  • Table 3-4: Near Patient Molecular Systems Market, 2023-2028 ($M, %)
• Market Share Near Patient
  • Figure 3-3: Market Share, Near Patient Molecular Testing
  • Table 3-5: Market Share, Near Patient Molecular Testing, by Vendor (Abbott, bioMerieux, Cepheid, Roche, Other), 2023 (%)

Chapter 4: Company Profiles

• Abbott Laboratories
• Aidian Oy
• Akonni Biosystems
• binx health, inc.
• Biocartis NV
• bioMerieux SA
  • Table 4-1: bioMerieux FilmArray Est. Systems per Quarter, Q4 '18-Q3 '23
  • Figure 4-1: FilmArray Systems Installed by Quarter, Q4 2018-Q3 2022
• Cepheid (Danaher)
• Molecular Healthcare-Acquired Infection (HAI) Testing
• Molecular Sexual Health and Women's Health Testing
• Molecular Critical Infectious Disease Testing
• Molecular Oncology/Genetics Testing
• Credo Diagnostics Biomedical Pte. Ltd.
• Cue Health
• Curetis NV (OpGen)
• DiaSorin S.p.A
• GenMark Diagnostics (Roche)
• Greiner Bio-One GmbH
• Lucira Health (Pfizer)
• Meridian Bioscience, Inc. (SD Biosensor)
• Mesa Biotech, Inc. (Thermo)
• QIAGEN NV
• QuantuMDx Group
• QuidelOrtho Corporation
• Roche
• Sekisui Diagnostics LLC
• T2 Biosystems